EPS3.06 Safety, pharmacokinetics and pharmacodynamics of the CFTR corrector FDL169

Horsley, A.; Burr, Lucy; Kotsimbos, Tom; Ledson, M.; Schwarz, C.; Simmonds, N.J.; O’Toole, Timothy E.; Kolodziej, Angela; Ordoñez, Claudia L.; Bell, Steve J. D.

doi:10.1016/s1569-1993(18)30251-0

Cited by 5 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar results were obtained by PM density measurement for P67L- and L206W-CFTR, and the small increase in S549R-CFTR PM density upon addition of VX-445 to the type I corrector treatment reached significance in this assay ( Figure 1 C). Since the PM density assay allows for higher-throughput measurements, we also determined the effect of the type I correctors ABBV-2222 and FDL-169, which are in clinical development [ 42 , 43 ]. Similar to its effect on E92K-CFTR [ 27 ], ABBV-2222 exhibited higher efficacy to correct the folding defect of P67L- and L206W-CFTR in comparison to other type I correctors ( Figure 1 C).…”

Section: Resultsmentioning

confidence: 99%

A Precision Medicine Approach to Optimize Modulator Therapy for Rare CFTR Folding Mutants

Veit

Velkov

et al. 2021

JPM

View full text Add to dashboard Cite

Trikafta, a triple-combination drug, consisting of folding correctors VX-661 (tezacaftor), VX-445 (elexacaftor) and the gating potentiator VX-770 (ivacaftor) provided unprecedented clinical benefits for patients with the most common cystic fibrosis (CF) mutation, F508del. Trikafta indications were recently expanded to additional 177 mutations in the CF transmembrane conductance regulator (CFTR). To minimize life-long pharmacological and financial burden of drug administration, if possible, we determined the necessary and sufficient modulator combination that can achieve maximal benefit in preclinical setting for selected mutants. To this end, the biochemical and functional rescue of single corrector-responsive rare mutants were investigated in a bronchial epithelial cell line and patient-derived human primary nasal epithelia (HNE), respectively. The plasma membrane density of P67L-, L206W- or S549R-CFTR corrected by VX-661 or other type I correctors was moderately increased by VX-445. Short-circuit current measurements of HNE, however, uncovered that correction comparable to Trikafta was achieved for S549R-CFTR by VX-661 + VX-770 and for P67L- and L206W-CFTR by the VX-661 + VX-445 combination. Thus, introduction of a third modulator may not provide additional benefit for patients with a subset of rare CFTR missense mutations. These results also underscore that HNE, as a precision medicine model, enable the optimization of mutation-specific modulator combinations to maximize their efficacy and minimize life-long drug exposure of CF patients.

show abstract

Section: Resultsmentioning

confidence: 99%